Healthcare · Pharmaceuticals & Biotechnology
QVM read Momentum-led Quality Moderate, Valuation Expensive, Momentum Bullish
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Ranks #174 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 22 Jun 2026 | USHA JAWAHARLAL KALRO | Bulk | Buy | 9,124 | 94.7100 | BSE |
| 22 Jun 2026 | USHA JAWAHARLAL KALRO | Bulk | Sell | 9,124 | 98.2300 | BSE |
| 11 Apr 2025 | DIVYA KANDA | Bulk | Buy | 10,370 | 119.7200 | BSE |
| 24 Mar 2025 | SUDHANSHU KANDA | Bulk | Buy | 8,000 | 115.1400 | BSE |
| 3 Dec 2024 | USHA JAWAHARLAL KALRO | Bulk | Sell | 9,241 | 91.2600 | BSE |
| 3 Dec 2024 | USHA JAWAHARLAL KALRO | Bulk | Buy | 9,302 | 88.2600 | BSE |
| 2 Sep 2024 | RAVAL NAMAN VIRENDRAKUMAR | Bulk | Sell | 13,855 | 80.9000 | BSE |
| 2 Sep 2024 | MAHENDRABHAI GULABDAS PATEL | Bulk | Buy | 15,045 | 80.5600 | BSE |
| 30 Aug 2024 | MAHENDRABHAI GULABDAS PATEL | Bulk | Buy | 4,105 | 75.7100 | BSE |
| 30 Aug 2024 | RAVAL NAMAN VIRENDRAKUMAR | Bulk | Buy | 13,855 | 71.0000 | BSE |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| — | NAME_CHANGE | Name changed from Chemo Pharma Laboratories Ltd. to STARSOURCE MULTITRADE LIMITED |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 29 Sep 2026 | AGM/EGM | Star Source Multi Trade Ltd - 506365 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report |
| 28 Sep 2026 | AGM/EGM | Star Source Multi Trade Ltd - 506365 - Shareholder Meeting / Postal Ballot-Outcome of AGM |
| 1 Sep 2026 | Board Meeting | Star Source Multi Trade Ltd - 506365 - Board Meeting Outcome for Outcome Of Board Meeting |
| 1 Sep 2026 | Corp. Action | Star Source Multi Trade Ltd - 506365 - Annual Book Closure For AGM For FY 2025-26 |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
